Human Microbiome Market - Snapshot

The human microbiome market exhibits significant potential in the near future due to huge untapped medical needs. The market is set to create lucrative opportunities due to a large number of ongoing clinical trials and entry of new players in the market. Presently, the human microbiome market is in the nascent stage, and therapies are still in the pre-clinical and clinical stage. Diagnostics is also in the development phase of the product life cycle. In November 2016, uBiome launched the SmartGut test for diagnosis of gut health disorders. Companies have begun to allocate significant funds for research and development and management of clinical studies for innovative therapies. Lack of targeted drugs in the market for specific conditions, such as C.difficile infection and ulcerative colitis, makes it a highly opportune condition for players to set their innovative drug ideas on the path of commercial success. The human microbiome comprises genetic material within a microbiota (the entire collection of microorganisms, such as bacteria, virus, fungi, archea, etc. in specific areas of the human body, such as the gut, vagina, oral cavity, etc.). The human microbiome market is driven by factors, such as rise in clinical trials for gut health-based diseases and increase in funds by investors or venture capital firms/individual venture capitalists for research and development on human microbiome-based therapies. However, the present lack of certainty in the performance of these drugs in the long-run and regulatory hurdles are anticipated to restrain the growth of the market during the forecast period. Nevertheless, the human microbiome diagnostics market is anticipated to be driven by rising preference of patients for descriptive, rapid, and non-invasive sequencing-based microbiome tests for diseases such as colon cancer, vaginosis, and Crohn’s disease.

human-microbiome-market.jpg

The global human microbiome diagnostics market is projected to expand at a robust CAGR of 9.8% during the forecast period, i.e. between 2018 and 2026, while the human microbiome therapeutics market is likely show similar exceptional growth with a CAGR of 9.6% during the forecast period from 2020 to 2026. Driven by huge unmet clinical needs for disease management and rising research and development expenditure; the global human microbiome diagnostics market is anticipated to be valued at US$ 892.1 Mn in 2018. It is expected to reach a value of US$ 1,888.9 Mn by 2026, reflecting a CAGR of 9.8%, while the global human microbiome therapeutics market is anticipated to be valued at US$ 1,245.3 Mn in 2020. It is expected to reach a value of US$ 2,160.9 Mn by 2026, registering a CAGR of 9.6%.

Based on therapeutic area, the human microbiome therapeutics market has been segmented into gastrointestinal disorders, metabolic disorders, women’s health, skin disorders, and others. The others segment includes therapeutic areas for infant health, infections and autoimmune diseases, and rare diseases. The gastrointestinal disorders segment is likely to capture the leading position in the market and exhibit high attractiveness due to the presence of a large number of therapies under clinical trials directed toward treating gastrointestinal disturbances, coupled with the existing unmet medical needs in gut health concerns. According to the CDC, on the basis of a study conducted in 2015, in the U.S., approximately 1 out of every 11 patients, over 65 years of age with C. difficile, dies within 30 days of diagnosis, which is an alarming figure. The CDC also estimated that about one of five patients had a recurrence of the illness. Thus, therapies such as SER-109, targeted toward the prevention of recurrent clostridium difficile infection (CDI) has shown promising results in clinical trials with less reoccurrence rate. This provides lucrative opportunities during the forecast period. The gastrointestinal diseases segment is likely to capture over 59.7% of the global human microbiome therapeutics market in 2020.

The global human microbiome diagnostics market has been segmented on the basis of indication, technology, and region. The gastrointestinal and metabolic disorders segments are projected to exhibit a total incremental opportunity of US$ 586.9 Mn from 2018 to 2026. Launch of tests aimed at diagnosing gut health imbalances and disorders, such as SmartGut by uBiome, is likely to propel the segment during the forecast period.

Key companies profiled in the report include AOBiome LLC, Osel, Inc., Seres Therapeutics, Second Genome, uBiome, Inc., Metabiomics Corp., Rebiotix, Inc., Vedanta Biosciences, Enterome, Biosciences, and Synthetic Biologics, Inc.

Human Microbiome Market - Overview

Human microbiome, also known as microbiota, includes microbes such as fungi, bacteria, and virus. These microbes reside in oral mucosa, saliva, gastrointestinal tracts, conjunctiva, or on the surface or in deep layers of the skin. At present, extensive research is being conducted to discover the importance of these micro-organisms in maintaining immune systems and their contribution in digestion of food. Large number of microbes reside in the large intestine, with region of the human body having a distinct community of microbes dwelling. Studies are still in progress to understand factors regulating microbial colonization in the body that are just millimeters apart. The human microbiome project (HMP) was launched in 2008 as a U.S. National Institute of Health. This was initiated to identify and characterize microbes found in the healthy and diseases human body.

This report on the global human microbiome market analyzes the future prospects of the market. The market for diagnostics and therapeutics is independently analyzed as two separate markets within the report. The market for human microbiome therapeutics is segmented based on therapeutic area and region, while the market for human microbiome diagnostics is segmented in terms of indication, technology, and region. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. A detailed qualitative analysis of factors driving and restraining the market and opportunities is provided in the market overview section. Market revenue in terms of US$ Mn for the period between 2018 and 2026 for diagnostics and 2020 to 2026 for therapeutics, along with the compound annual growth rate (CAGR %) from 2018/2020 to 2026 are provided for all the segments. Market related factors such as estimated launch of products, drugs in the pipeline, and industry-institute collaborations in research have been taken into consideration while estimating the market size. Growth rate for each segment within the global human microbiome market has been determined after a thorough analysis of past and present trends, demographics, future trends, technological developments, clinical trials, and regulatory requirements. These factors are projected to help market players to take strategic decisions to strengthen their positions and increase share in the global market.

Based on indication, the global human microbiome diagnostics market has been segmented into gastrointestinal and metabolic disorders, women’s health, cancer, and others. The gastrointestinal & metabolic disorders segment is projected to expand at a considerable pace due to high unmet medical needs for gut health disorders and rise in population suffering from lifestyle-based metabolic diseases. In terms of technology, the market has been bifurcated into 16s rRNA sequencing and metagenomic sequencing. Both these forms have been documented to have various advantages and provide accurate testing and hence, these are likely to garner nearly equal share of the overall diagnostics market during the forecast period. Based on therapeutic area, the market has been segmented into gastrointestinal disorders, metabolic disorders, women’s health, skin disorders, and others. The others segment includes autoimmune disorders, infant health disorders, and rare diseases.

In terms of region, the global human microbiome market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Additionally, the regions have been further segmented by major countries. These include the U.S., Canada, the U.K., Germany, China, Japan, Brazil, Mexico, the UAE, and South Africa. The competition landscape section included in the report is likely to assist existing players increase their market shares and new companies to establish their presence in the human microbiome market. The report profiles major players operating in the human microbiome market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include AOBiome LLC, Osel, Inc., Seres Therapeutics, Second Genome, uBiome, Inc., Metabiomics Corp., Rebiotix, Inc., and Vedanta Biosciences.

The global human microbiome market has been segmented as follows:

Global Human Microbiome Diagnostics Market, by Indication

  • Gastrointestinal and Metabolic Disorders
  • Women’s Health
  • Cancer
  • Others

Global Human Microbiome Diagnostics Market, by Technology

  • 16s rRNA Sequencing
  • Metagenomic Sequencing

Global Human Microbiome Therapeutics Market, by Therapeutic Area

  • Gastrointestinal Disorders
  • Metabolic Disorders
  • Women’s Health
  • Skin Disorders
  • Others

Global Human Microbiome Diagnostics and Therapeutics Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • UAE
    • South Africa
    • Rest of Middle East & Africa
.